Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Osteosarcoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Myelosuppression 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

Pemetrexed 9Drug Therapy 9osimertinib 7Radiotherapy 6Carboplatin 6anlotinib 5Radiosurgery 5aflutinib 4Gefitinib 4Docetaxel 4Cisplatin 4tislelizumab 3pembrolizumab 3icotinib 3Vinorelbine 3Paclitaxel 3Gemcitabine 3Erlotinib Hydrochloride 3toripalimab 2dacomitinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Liquid Biopsy 2Immune Checkpoint Inhibitors 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × NSCLC × trilaciclib × Clear all
NCT06328049 2024-03-25

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Taixing People's Hospital

Phase 2 Unknown
30 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡